Revefenacin, sold under the brand name Yupelri, is a medication for the treatment of chronic obstructive pulmonary disease (COPD). It was approved for use in the United States in 2018.[1] It was developed by Theravance Biopharma and is marketed by Mylan. Revefenacin is formulated as a solution that is nebulized and inhaled.[2]
Clinical data | |
---|---|
Trade names | Yupelri |
AHFS/Drugs.com | Monograph |
MedlinePlus | a619009 |
License data |
|
Routes of administration | Inhalation |
ATC code |
|
Legal status | |
Legal status |
|
Identifiers | |
CAS Number |
|
PubChem CID |
|
DrugBank |
|
ChemSpider |
|
UNII |
|
KEGG |
|
Chemical and physical data | |
Formula | C35H43N5O4 |
Molar mass | 597.760 g·mol−1 |
3D model (JSmol) |
|
| |
|
Revefenacin is a bronchodilator that exerts its effect as a long-acting muscarinic antagonist.[3]